|Articles|February 15, 2002
- BioPharm International-02-01-2002
- Volume 15
- Issue 2
Inside Washington: Costs and Controls Challenge Manufacturers
Author(s)Jill Wechsler
By Jill Wechsler, pp. 52-56. More curbs on reimbursement for expensive, cutting-edge therapies may shape R&D programs and industry growth
Advertisement
Articles in this issue
almost 24 years ago
Sale of Your Product Can Prevent Patenting: How to Avoid the On-Sale Baralmost 24 years ago
Outsourcing Outlook: Reaping the Benefits of E-Procurementalmost 24 years ago
The Immunogenicity of Therapeutic Proteinsalmost 24 years ago
Analytical Advances: Calibration Management of Outsourced Calibrationsalmost 24 years ago
21 CFR Part 11: (Un)Expected Added ValueNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
BioPharma By The Numbers: Batch Failures in Biopharma Manufacturing
2
Charles River Incubator Cohort to Accelerate CGT Development
3
Developing Next-Gen Cell Lines Using Targeted Integration
4
Two-Minute Mysteries: BioPharm Stories - Episode 2: The Costly Myth of Noninvasive Glucose Monitoring
5
